evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

134 questions · 135 findings · 46 reviews

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 31 · 23%GRADE not reported 24 · 17.8%Very low 17 · 12.6%Low 24 · 17.8%Moderate 35 · 25.9%High 4 · 3%

Tocilizumab weekly vs placebo + 52‐week taper

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab weekly vs placebo + 26‐week taper

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every other week vs placebo + 52‐week taper

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every other week vs placebo + 26‐week taper

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

Tocilizumab every other week showed no clear difference in mean change in VAS (higher scores suggest greater disease activity… compared with placebo + 26‐week taper (moderate certainty).

1 finding from 1 review

Tocilizumab every 4 weeks vs placebo

Mean change in VAS (higher scores suggest greater disease activity and worse quality of life) at ≥ 12 months · adults aged over 50 years with giant cell arteritis

The review found no eligible studies for this question.

1 finding from 1 review

PIMOZIDE vs placebo

Quality of life: no significant change in quality of life/satisfaction medium term (3‐12 months) not reported · patients with schizophrenia or related psychoses

The review found no eligible studies for this question.

1 finding from 1 review

Rivastigmine vs placebo

Quality of life of patients or carers (measured using NPI‐D carer distress scale (change from baseline at 24 weeks) · Apathy in people with mild‐to‐moderate Alzheimer's disease
1 finding from 1 review

Tocilizumab weekly vs placebo + 52‐week taper

Mean change in quality of life at ≥ 12 months using the 36‐Item Short Form Health Survey mental component score (SF‐36 MCS) · adults aged over 50 years with giant cell arteritis

Tocilizumab weekly probably leads to higher mean change in quality of life at ≥ 12 months using the 36‐Item… compared with placebo + 52‐week taper (moderate certainty).

1 finding from 1 review